

REFERENCES

- 1) American Society of Clinical Oncology. (2021, January). *Breast Cancer: Statistics / Cancer.Net*. <https://www.cancer.net/cancer-types/breast-cancer/statistics>
- 2) Anampa, J., Makower, D., & Sparano, J. A. (2015). Progress in adjuvant chemotherapy for breast cancer: an overview. *BMC Medicine*, 13(1). <https://doi.org/10.1186/S12916-015-0439-8>
- 3) Anwar, S. L., Avanti, W. S., Nugroho, A. C., Choridah, L., Dwianingsih, E. K., Harahap, W. A., Aryandono, T., & Wulaningsih, W. (2020). Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. *World Journal of Surgical Oncology*, 18(1). <https://doi.org/10.1186/S12957-020-01893-W>
- 4) Bansal, C., Singh, U. S., Misra, S., Sharma, K. L., Tiwari, V., & Srivastava, A. N. (2012). Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology. *CytoJournal*, 9(1). <https://doi.org/10.4103/1742-6413.92550>
- 5) Board, P. A. T. E. (2021). Breast Cancer Treatment (Adult) (PDQ®). *PDQ Cancer Information Summaries*, 1–5. <https://www.cancer.gov/types/breast/patient/breast-treatment-pdq>
- 6) Candido dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., van den Broek, A. J., Ellis, I. O., Green, A., Rakha, E., Maishman, T., Eccles, D. M., & Pharoah, P. D. P. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, 19(1), 1–13. <https://doi.org/10.1186/S13058-017-0852-3/FIGURES/4>
- 7) Colzani, E., Johansson, A. L. V., Liljegren, A., Foukakis, T., Clements, M., Adolfsson, J., Hall, P., & Czene, K. (2014). Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. *British Journal of Cancer*, 110(5), 1378. <https://doi.org/10.1038/BJC.2014.5>
- 8) Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype classification, clinical use and future trends. *American Journal of Cancer Research*, 5(10), 2929. [/pmc/articles/PMC4656721/](https://pubmed.ncbi.nlm.nih.gov/261465672/)

- 9) DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Sauer, A. G., Jemal, A., & Siegel, R. L. (2019). Breast cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, 69(6), 438–451. <https://doi.org/10.3322/CAAC.21583>
- 10) Ernard, B., Isher, F., Nderson, T. A., Ohn, J., Ryant, B., Argolese, I. G. M., Eutsch, E. D., Isher, D. R. F., Ong -H Yeon, J., Eong, J., Orman, N., & Olmark, W. (2009). Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. *Http://Dx.Doi.Org/10.1056/NEJMoa022152*, 347(16), 1233–1241. <https://doi.org/10.1056/NEJMoa022152>
- 11) Fouad, Y. A., & Aanei, C. (2017). Revisiting the hallmarks of cancer. *American Journal of Cancer Research*, 7(5), 1016. /pmc/articles/PMC5446472/
- 12) Gong, G., Kwon, M. J., Han, J., Lee, H. J., Lee, S. K., Lee, J. E., Lee, S. H., Park, S., Choi, J. S., Cho, S. Y., Ahn, S. H., Lee, J. W., Cho, S. R., Moon, Y., Nam, B. H., Nam, S. J., Choi, Y. la, & Shin, Y. K. (2017). A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. *Scientific Reports 2017 7:1*, 7(1), 1–11. <https://doi.org/10.1038/srep45554>
- 13) Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, 100(1), 57–70. [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9)
- 14) Hassan, O., Nagi, C., Allred, D. C., Harris, L., & Bossuyt, V. (2019, March 20). *What is the Nottingham combined histologic grade (modified Scarff-Bloom-Richardson grade) system for breast tumours?* <https://www.medscape.com/answers/1668113-181367/what-is-the-nottingham-combined-histologic-grade-modified-scarff-bloom-richardson-grade-system-for-breast-tumours>
- 15) Higgins, M. J., & Baselga, J. (2011). Targeted therapies for breast cancer. *The Journal of Clinical Investigation*, 121(10), 3797. <https://doi.org/10.1172/JCI57152>
- 16) Holm, J., Li, J., Darabi, H., Eklund, M., Eriksson, M., Humphreys, K., Hall, P., & Czene, K. (2016). Associations of breast cancer risk prediction tools with tumour characteristics and metastasis. *Journal of Clinical Oncology*, 34(3), 251–258. <https://doi.org/10.1200/JCO.2015.63.0624>
- 17) Ikeda, T., Jinno, H., & Kitajima, M. (2004). The evolution of primary chemotherapy in breast cancer treatment. *Breast Cancer (Tokyo, Japan)*, 11(2), 148–155. <https://doi.org/10.1007/BF02968294>

- 18) Kementerian Kesehatan Republik Indonesia. (2019). *Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia – P2P Kemenkes RI*. <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/>
- 19) Langley, R. R., & Fidler, I. J. (2011). The seed and soil hypothesis revisited - the role of tumour-stroma interactions in metastasis to different organs. *International Journal of Cancer. Journal International Du Cancer*, 128(11), 2527. <https://doi.org/10.1002/IJC.26031>
- 20) Li, L. T., Jiang, G., Chen, Q., & Zheng, J. N. (2015). Predict Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Molecular Medicine Reports*, 11(3), 1566–1572. <https://doi.org/10.3892/MMR.2014.2914/HTML>
- 21) Liu, Q., Zhang, H., Jiang, X., Qian, C., Liu, Z., & Luo, D. (2017). Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. *Molecular Cancer 2017 16:1*, 16(1), 1–19. <https://doi.org/10.1186/S12943-017-0742-4>
- 22) Longo, D. (2017). *Harrison’s Hematology and Oncology* (D. L. Kasper, A. S. Fauci, S. Hauser, J. L. Jameson, J. Loscalzo, & D. Longo, Eds.; 3rd ed.). McGraw-Hill Education.
- 23) Mandrekar, J. N. (2010). Receiver Operating Characteristic Curve in Diagnostic Test Assessment. *Journal of Thoracic Oncology*, 5(9), 1315–1316. <https://doi.org/10.1097/JTO.0B013E3181EC173D>
- 24) Maughan, K. L., Lutterbie, M. A., & Ham, P. S. (2010). Treatment of Breast Cancer. *Am Fam Physician*, 81(11), 1339–1346. www.aafp.org/afpAmericanFamilyPhysician1339
- 25) Mitri, Z., Constantine, T., & O’Regan, R. (2012). The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. *Chemotherapy Research and Practice*, 2012, 1–7. <https://doi.org/10.1155/2012/743193>
- 26) Morris, G. J., & Mitchell, E. P. (2007). Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. *Journal of the National Medical Association*, 99(1), 35. [/pmc/articles/PMC2569609/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/16111111/)
- 27) National Cancer Institute. (2021). *Female Breast Cancer — Cancer Stat Facts*. <https://seer.cancer.gov/statfacts/html/breast.html>

- 28) National Cancer Institute. (n.d.). *Definition of estrogen receptor - NCI Dictionary of Cancer Terms - National Cancer Institute*. Retrieved January 10, 2022, from <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/estrogen-receptor>
- 29) National Health Service UK. (2019, October 28). *Breast cancer in women - Treatment - NHS*. <https://www.nhs.uk/conditions/breast-cancer/treatment/>
- 30) National Health Service UK. (2018, August 29). *Menopause*. <https://www.nhs.uk/conditions/menopause/>
- 31) *Predict Breast*. (n.d.). Retrieved January 10, 2022, from <https://breast.predict.nhs.uk/>
- 32) Redig, A. J., & Mcallister, S. S. (2013). Breast cancer as a systemic disease: a view of metastasis. *Journal of Internal Medicine*, 274(2), 113. <https://doi.org/10.1111/JOIM.12084>
- 33) Rivera-Franco, M. M., & Leon-Rodriguez, E. (2018). Delays in Breast Cancer Detection and Treatment in Developing Countries. <https://doi.org/10.1177/1178223417752677>
- 34) Schisterman, E. F., Perkins, N. J., Liu, A., & Bondell, H. (2005). Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples. *Epidemiology*, 16(1), 73–81. <https://doi.org/10.1097/01.EDE.0000147512.81966.BA>
- 35) Seyfried, T. N., & Huysentruyt, L. C. (2013). On the Origin of Cancer Metastasis. *Critical Reviews in Oncogenesis*, 18(1–2), 43. <https://doi.org/10.1615/CritRevOncog.v18.i1-2.40>
- 36) Shah, R., Rosso, K., & David Nathanson, S. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology*, 5(3), 283. <https://doi.org/10.5306/WJCO.V5.I3.283>
- 37) Simon, A., & Robb, K. (2021). Breast Cancer. *Cambridge Handbook of Psychology, Health and Medicine, Second Edition*, 577–580. <https://doi.org/10.1017/CBO9780511543579.131>
- 38) Wang, Y., Yang, Y., Chen, Z., Zhu, T., Wu, J., Su, F., & Deng, H. (2019). Development and validation of a novel nomogram for predicting distant metastasis-free survival among breast cancer patients. *Annals of Translational Medicine*, 7(20), 537–537. <https://doi.org/10.21037/ATM.2019.10.10>

- 39) Wong, H. S., Subramaniam, S., Alias, Z., Taib, N. A., Ho, G. F., Ng, C. H., Yip, C. H., Verkooijen, H. M., Hartman, M., & Bhoo-Pathy, N. (2015). The Predictive Accuracy of PREDICT: A Personalized Decision-Making Tool for Southeast Asian Women With Breast Cancer. *Medicine*, 94(8), e593. <https://doi.org/10.1097/MD.0000000000000593>
- 40) World Health Organization. (2021). *Breast cancer*. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- 41) World Health Organization. (n.d.). *Cancer*. Retrieved January 10, 2022, from https://www.who.int/health-topics/cancer#tab=tab_1